Accessibility Menu
Invex Therapeutics logo

Invex Therapeutics(ASX) IXC

Market CapA$8.64MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-58%
5 Year-28%
1 Year+53%
1 Month+10%
A$0.12
+0.00%
+0.00Today
Invex Therapeutics last closing stock price
MetricPriceDate
Last closeAUD 0.122026-08-14
Invex Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%AUD 0.122026-08-07
1 month+9.52%AUD 0.112026-07-06
3 month-8%AUD 0.132026-05-15
Year to date-4.17%AUD 0.122025-12-30
1 year+53.33%AUD 0.082025-08-13
3 year+150.74%AUD 0.052023-08-15
5 year-28.36%AUD 0.162021-08-13
Since inception-58.02%AUD 0.272019-07-05

Invex Therapeutics Financials at a Glance

Market Cap

A$8.64MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$1.44M

Net Income (TTM)

-A$722.03K

EPS (TTM)

-A$0.01

P/E Ratio

-10.36

Dividend

A$0.00

Beta (Volatility)

-0.17 (Low)

Price

A$0.12

Volume

6,250

Open

A$0.12

Previous Close

A$0.12

Daily Range

A$0.12 - A$0.12

52-Week Range

A$0.09 - A$0.18

Estimated Earnings Date

Aug 13, 2026

IXC News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Invex Therapeutics

Invex Therapeutics Ltd is an Australian biopharmaceutical company focused on developing innovative treatments for neurological disorders. The company primarily targets conditions associated with elevated intracranial pressure, utilizing Exenatide, which has shown promise in Phase II clinical trials.

Products and Services
  • Exenatide for treating idiopathic intracranial hypertension
  • Research and development of therapies for acute stroke
  • Innovative solutions for traumatic brain injury
Growth Outlook
  • Exenatide has advanced through Phase II clinical trials, indicating potential market readiness
  • Focus on neurological disorders presents significant unmet medical needs
  • Strong pipeline could lead to strategic partnerships and collaborations
Financial Highlights
  • Recent quarterly revenue of AUD 0, reflecting ongoing R&D investments
  • Cash and cash equivalents of AUD 4.6 million as of December 2025
  • Current ratio of 26.76, indicating strong liquidity position
Invex Therapeutics Ltd operates in the biotechnology sector, emphasizing the development of treatments for serious neurological conditions. The company's lead product, Exenatide, has shown potential in clinical trials, which could position it favorably in a market with significant unmet needs. The focus on innovative therapies for conditions like idiopathic intracranial hypertension and acute stroke highlights the company's commitment to addressing critical health challenges. Financially, Invex Therapeutics is in a phase of heavy investment in research and development, as evidenced by its recent quarterly results showing no revenue but substantial R&D expenses. The company maintains a robust liquidity position with a current ratio of 26.76, suggesting it has ample resources to support ongoing operations and development efforts. The cash reserves of AUD 4.6 million provide a cushion for future growth initiatives. Overall, Invex Therapeutics Ltd presents an intriguing opportunity for investors interested in the biotechnology sector, particularly in companies focused on innovative solutions for neurological disorders. The potential for strategic partnerships and the advancement of its clinical pipeline could drive future growth and value creation.
AI Generated • Jul 18, 2026

Industry

Pharmaceuticals

Sector

Health Care

Website

www.invextherapeutics.com

Headquarters

Subiaco, WA 6008, AU

IXC Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-471.50%

Net Income Margin

-364.89%

Return on Equity

-17.07%

Return on Capital

-13.52%

Return on Assets

-17.70%

Earnings Yield

-9.65%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$8.64MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

75.15M

Volume

6.25K

Avg. Volume

30.31K

Financials (TTM)

Gross Profit

A$1.44M

Operating Income

-A$1.20M

EBITDA

-A$1.94M

Operating Cash Flow

-A$1.56M

Capital Expenditure

A$0.00

Free Cash Flow

-A$1.56M

Cash & ST Invst.

A$4.60M

Total Debt

A$0.00

Invex Therapeutics Performance Analysis

Invex Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30AUD 0N/A
20232023-06-30AUD 0N/A
20242024-06-30AUD 0N/A
20252025-06-30AUD 0N/A
Invex Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30N/A
Q22024-12-31-100.0%
Q42025-06-30N/A
Q22025-12-31-100.0%
Invex Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30AUD -0.05N/A
20232023-06-30AUD -0.1096.0%
20242024-06-30AUD -0.02-78.9%
20252025-06-30AUD -0.01-70.6%
Invex Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30122.1%
Q22024-12-31-175.8%
Q42025-06-3066.0%
Q22025-12-31-493.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

A$0.00

N/A

Gross Profit

A$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

A$8.64MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$2.16M

N/A

Employees

4

N/A

Net Income

-A$715.58K

+66.1%

EBITDA

-A$843.02K

-323.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

A$4.60M

-25.3%

Total Debt

A$0.00

N/A

Accounts Receivable

A$128.00K

-0.5%

Inventory

A$0.00

N/A

Long Term Debt

A$0.00

N/A

Short Term Debt

A$0.00

N/A

Return on Assets

-17.70%

N/A

Return on Invested Capital

-23.76%

N/A

Free Cash Flow

-A$779.73K

+66.4%

Operating Cash Flow

-A$779.73K

+66.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
VBS.AXVectus Biosystems Limited
A$0.16+0.00%
BGT.AXBio-Gene Technology Limited
A$0.02+0.00%
ACR.AXAcrux Limited
A$0.01+0.00%
PER.AXPercheron Therapeutics Limited
A$0.01+11.11%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$15.23+0.09%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.76+0.01%
ONDSOndas
$9.24+0.04%
SPCXSpace Exploration Technologies
$140.00-0.01%

Questions About IXC

What is the current price of Invex Therapeutics?

Invex Therapeutics is trading at A$0.12 per share.

What is the 52-week range for Invex Therapeutics?

Over the past 52 weeks, Invex Therapeutics has traded between A$0.09 and A$0.18.

How much debt does Invex Therapeutics have?

As of the most recent reporting period, Invex Therapeutics reported total debt of A$0.00.

How much cash does Invex Therapeutics have on hand?

Invex Therapeutics reported A$5.38M in cash and cash equivalents in its most recent financial results.

What is Invex Therapeutics’s dividend yield?

Invex Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services